Global Biometrics Clinical Research Organization Quanticate Appoints Dr. Alison Bond To Lead Pharmacovigilance

CAMBRIDGE, MA and LONDON--(Marketwire -Underwood. "Alison brings several years of
February 9, 2010) - Quanticate, a global biometricsexperience and a depth of knowledge in this
clinical research organization (CRO), today announcedimportant area of drug development. Her leadership
that it has appointed Dr. Alison Bond to lead its newof our Pharmacovigilance Services will be of great
Pharmacovigilance Services team. The appointmentvalue to our customers."
further supports Quanticate's mission in continuing toPrior to joining Quanticate, Alison served as an
expand its clinical trial services offerings to supportindependent pharmacovigilance consultant, leading the
customers around the world.set-up of pharmacovigilance systems and completion
The new pharmacovigilance service offers clinical trialof pharmacovigilance aspects of an EU Marketing
and post-marketing pharmacovigilance in order toAuthorization Application for a small biopharmaceutical
provide comprehensive surveillance throughout thecompany. Prior to that assignment, she contributed
product lifecycle. These services include adverseeight years of service to PAREXEL International, one
event case management and reporting, signalof the leading global biopharmaceutical service
detection and evaluation, literature screening andproviders, holding senior management positions in
review, and pharmacovigilance document preparationMedical & Pharmacovigilance. In these roles, Alison
and submission, such as Annual Safety Reports,created and managed global pharmacovigilance
Periodic Safety Update Reports and Risksystems for a number of pharmaceutical and biotech
Management Plans.companies, through all phases of clinical development
"Centralizing clinical and safety data with Quanticateand post-marketing. Alison also led the UK team of
creates efficiencies for our customers -- hence theDrug Safety Scientists and helped to develop and
addition of pharmacovigilance services. This signalsimprove systems and processes for their global
another exciting development for Quanticate and ourpharmacovigilance services. She gained a PhD in the
customers who need to implement rigorous programsfield of rheumatology and has nine years of
that meet regulatory requirements and protectpre-clinical research experience.
patients," said Quanticate's CEO David